Arthritis, RheumatoidPhase 3ORAL1069NCT01039688
Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX
A Phase 3 study testing CP-690,550 and Disease-modifying antirheumatic drug in people with Arthritis, Rheumatoid, run by Pfizer at 176 sites in 30 countries.
Trial summary
This study is designed to compare the effectiveness of the experimental drug, CP-690,550, to methotrexate in preventing joint damage and improving symptoms of rheumatoid arthritis. This study will also compare the safety of CP-690,550 with methotrexate. Read more about this study
- Who is it for?
- Ages 18 to 99 years
- Conditions the study is for
- Arthritis, Rheumatoid
- What is being tested?
- CP-690,550 and Disease-modifying antirheumatic drug
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 956 participants
- Where
- 176 sitesin 30 countries
- Study dates
- Jan 2010to Mar 2013
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults with moderate to severe RA (Rheumatoid Arthritis) who have not been treated with methotrexate.
- Diagnosis of RA based on the American College of Rheumatology 1987 revised criteria.
- Active disease as defined by both >=6 tender or painful joints on motion and >= 6 joints swollen; and either an erythrocyte sedimentation rate (ESR) > 28 mm or a C-reactive protein (CRP) concentration > 7 mg/dL
Who cannot join
- Blood dyscrasias including confirmed: Hemoglobin <9 g/dL or Hematocrit <30%; White blood cell count <3.0 x 109/L; Absolute neutrophil count <1.2 x 109/L; Platelet count <100 x 109/L
- History of any other rheumatic autoimmune disease other than Sjogren's syndrome
- No malignancy or history of malignancy
- History of infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator, within the 6 months prior to the first dose of study drug
- No chronic liver disease, recent or active hepatitis or other contraindication to methotrexate therapy
Trial locations and contacts
176 sites in 30 countries.
176 sites in 30 countries
United States41 sites
The Center for Rheumatology
Albany, New York, 12206
Austin Rheumatology Research
Austin, Texas, 78705
Medical University of South Carolina - Rheumatology
Charleston, South Carolina, 29425
Medical University of South Carolina Investigational Drug Services
Charleston, South Carolina, 29425
Medical University of South Carolina
Charleston, South Carolina, 29425
Mountain State Clinical Research
Clarksburg, West Virginia, 26301
United Hospital Center (Imaging Only)
Clarksburg, West Virginia, 26301
Metroplex Clinical Research Center
Dallas, Texas, 75231
Medical Associates Clinic, PC
Dubuque, Iowa, 52002
Altoona Center for Clinical Research
Duncansville, Pennsylvania, 16635
University of North Texas Health Science Center at Fort Worth
Fort Worth, Texas, 76107
Southeastern Arthritis Center
Gainesville, Florida, 32607
Southeastern Imaging and Diagnostics
Gainesville, Florida, 32607
Southeastern Integrated Medical, PL dba Florida Medical Research
Gainesville, Florida, 32607
PMG Research of Hickory, LLC
Hickory, North Carolina, 28601
PMG Research of Hickory, LLC
Hickory, North Carolina, 28602
Diagnostic Rheumatology and Research, PC
Indianapolis, Indiana, 46227
Arthritis Clinic
Jackson, Tennessee, 38305
West Tennessee Research Institute
Jackson, Tennessee, 38305
University of California San Diego Perlman Ambulatory Clinic
La Jolla, California, 92037-0943
University of California San Diego Center for Innovative Therapy
La Jolla, California, 92093 0943
Physician Research Collaboration, LLC
Lincoln, Nebraska, 68516
Little Rock Diagnostic Clinic
Little Rock, Arkansas, 72205
Keck Hospital of USC, Lower Level Pharmacy
Los Angeles, California, 90033
Keck Hospital of USC
Los Angeles, California, 90033
USC Keck School of Medicine
Los Angeles, California, 90033
University of California Los Angeles (UCLA)
Los Angeles, California, 90095
Center for Arthritis and Rheumatic Diseases
Miami, Florida, 33173
Louisiana State University Health Sciences
New Orleans, Louisiana, 70115
Lynn Health Science Institute
Oklahoma City, Oklahoma, 73112
AAIR Research Center
Rochester, New York, 14618
Sarasota Arthritis Research Center
Sarasota, Florida, 34239
Investigational Drug Service
Seattle, Washington, 98101
Virginia Mason Medical Center
Seattle, Washington, 98101
West Broward Rheumatology Associates, Inc.
Tamarac, Florida, 33321
Bernard F. Germain, MD
Tampa, Florida, 33613
Burnette & Silverfield, MDS PLC
Tampa, Florida, 33614
Catalina Pointe Clinical Research, Inc.
Tucson, Arizona, 85704
The Center for Rheumatology and Bone Research
Wheaton, Maryland, 20902
Clinical Pharmacology Study Group
Worcester, Massachusetts, 01605
Clinical Research Center of Reading, LLP
Wyomissing, Pennsylvania, 19610
Russia14 sites
State Healthcare Institution Regional Clinical Hospital
Barnaul, 656024
State Healthcare Institution Regional Clinical Hospital for War Veterans
Kemerovo, 650099
Federal State Institution named after Academician E.N. Meshalkin, Novosibirsk State Research
Novosibirsk, 630055
Scientific Research Institute of Clinical and Experimental Lymphology of the Siberian Branch of RAMS
Novosibirsk, 630117
State Health Institution City Hospital # 25, City Rheumatology Center of St. Petersburg
Saint Petersburg, 190068
Clinical Hospital #122 named after L.G. Sokolov of the Federal Medical-Biological Agency
Saint Petersburg, 194291
Almazov Federal Heart, Blood and Endocrinology Centre
Saint Petersburg, 197341
State Healthcare Institution City Hospital # 40 of Administrative Health Resort District
Saint Petersburg, 197706
St. Petersburg State Institution of Healthcare Consultative-diagnostic Center #85
Saint Petersburg, 198260
Smolensk State Medical Academy, Clinical Research Centre of Diagnostic Medicine and Drugs
Smolensk, 214019
Regional State Healthcare Institution of Tomsk Regional Clinical Hospital
Tomsk, 634063
State Healthcare Institution
Yekaterinburg, 620102
Ltd. Medical Association "Novaya Bolnitsa" (X-Ray Only)
Yekaterinburg, 620109
State Educational Institution of Higher Professional Education
Yekaterinburg, 620149
Canada12 sites
Burlington Rheumatology and Osteoporosis Clinic
Burlington, Ontario, L7L 0B7
Rheumatology Research Associates Ltd.
Edmonton, Alberta, T5M 0H4
Dr. William G. Bensen Medicine Professional Corporation
Hamilton, Ontario, L8N 1Y2
Office of Dr. Fernando Bianchi
Hamilton, Ontario, L8N 1Y2
MAC Research Inc.
Hamilton, Ontario, L8N 2B6
KW Musculoskeletal Research Inc.
Kitchener, Ontario, N2M 5N6
Rheumatology Research Associates
Ottawa, Ontario, K1H 1A2
Niagara Peninsula Arthritis Centre
St. Catharines, Ontario, L2N 7E4
PerCuro Clinical Research Ltd.
Victoria, British Columbia, V8V 3P9
Windsor Radiological Associates
Windsor, Ontario, N8X 1K7
Clinical Research and Arthritis Centre
Windsor, Ontario, N8X 5A6
Manitoba Clinic
Winnipeg, Manitoba, R3A 1M3
Germany8 sites
Privat-Praxis, Rheumatologie (P515)
Aachen, 52064
Schlosspark-Klinik
Berlin, 14059
Studienambulanz, Medizinische Klinik 3 Universitaetsklinikum Erlangen
Erlangen, 91054
Schwerpunktpraxis Rheumatologie FAE Innere Medizin
Halle, 06108
Schoen Klinik Hamburg-Eilbek, Abt. Rheumatologie und Klin. Immunologie
Hamburg, 22081
Arztpraxis, Internist - Rheumatologie
Nuremberg, 90429
Rheumaforschung - Studienambulanz Dr. Wassenberg
Ratingen, 40882
Schwerpunktpraxis fuer Rheumatologie
Rheine, 48431
India7 sites
Rheumatic Disease Clinic
Ahmedabad, Gujarat, 380009
Shalby Hospital
Ahmedabad, 380015
Shirdi Sai Hospital
Bangalore, Karnataka, 560 054
Mahavir Hospital & Research Center
Hyderabad, Andhra Pradesh, 500 004
Arthritis Research and Care Foundation
Pune, Maharashtra, 411 001
Jehangir Clinical Development Centre Pvt. Ltd.
Pune, Maharashtra, 411 001
Department of Rheumatology
Secunderabad, Andhra Pradesh, 500003
Brazil6 sites
Centro de Estudos em Terapias Inovadoras
Curitiba, Paraná, 80060-240
CIP - Centro Internacional de Pesquisas
Goiânia, Goiás, 74110-120
Clinica de Raios X Nabyh Salum S/S - Clinica Sao Matheus
Goiânia, Goiás, 74115-030
Hospital Sao Lucas da PUCRS
Porto Alegre, Rio Grande do Sul, 90610-000
CCBR Brasil Centro de Pesquisas e Analises Clinicas Ltda
Rio de Janeiro, 22271-100
CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda
São Paulo, São Paulo, 04266-010
Bulgaria6 sites
Revmatologichno Otdelenie, MBAL - Plovdiv
Plovdiv, 4000
MBAL-Ruse, AD, IV Terapevtichno i kardiologichno otdelenie
Rousse, 7002
MBAL na Voennomeditsinska Akademia - Sofia, Klinika po Revmatologia i Kardiologia
Sofia, 1606
MBAL Sveti Ivan Rilski Sofia; Klinika po Revmatologia
Sofia, 1612
DKTs "Sveta Anna", Sofia; Konsultativen kabinet po Revmatologia
Sofia, 1709
MOBAL "D-r Stefan Cherkezov" AD, Revmokardiologichno otdelenie s intenziven sektor
Veliko Tarnovo, 5000
Czechia6 sites
Fakultni nemocnice Brno
Brno, 62500
Revmacentrum MUDr. Mostera, s.r.o.
Brno-Židenice, 61500
Fakultni nemocnice Hradec Kralove
Hradec Králové, 50005
Revmatologicka ambulance
Ostrava-Poruba, 70800
Revmatologicky ustav
Prague, 128 50
Revmatologicka ambulance
Prague, 140 00
Ukraine6 sites
State Institution "Republican Clinical Hospital of the Ministry of Health of Ukraine"
Kyiv, 04053
State Institution "Republican Clinical Hospital of the Ministry of Health of Ukraine"
Kyiv, 04114
Municipal City Clinical Hospital #4, Department of Rheumatology
Lviv, 79011
Municipal Establishment "City Clinical Hospital #9 n.a. O.I. Minakov", Department of Rheumatology
Odesa, 65026
CRI "Clinical Territorial Medical Association "University Clinic", Department of Rheumatology
Simferopol, Autonomous Republic of Crimea, 95017
Vinnitsa Regional Clinical Hospital n.a. M.I. Pirogov
Vinnitsa, 21018
Chile5 sites
Hospital Regional de Rancagua
Rancagua, 2841959
Centro de Estudios Reumatologicos
Santiago, RM, 7501126
Consulta Privada Dra. Marta Aliste
Santiago, RM, 7510186
Consulta Privada Dra. Lucia Ponce
Temuco, Araucania, 4790928
Estudios Clinicos V Region
Viña del Mar, Valparaiso, 2570017
Hungary5 sites
Drug Research Center Kft. Reumatologiai Szakrendeles
Balatonfüred, 8230
Revita Reumatologiai Rendelo
Budapest, 1027
Synexus Magyarorszag Kft.
Budapest, H-1036
Mozgasszervi Rehabilitacios Kozpont, Reumatologiai szakrendeles
Mezőkövesd, 3400
MAV Korhaz es Rendelointezet
Szolnok, H-5000
Poland5 sites
Przychodnia Medyczna Lekarskiej Spoldzielni Pracy
Gdynia, 81-367
Centrum Leczenia Chorob Cywilizacyjnych Sp. z.o.o. SKA Oddzial Gdynia
Gdynia, 81-384
Centrum Leczenia Chorob Cywilizacyjnych Sp. z o.o. SKA Oddzial Katowice
Katowice, 40-748
Synexus SCM Sp. z o.o. Oddzial Warszawa
Warsaw, 01-192
Rheuma Medicus - Specjalistyczne Centrum Reumatologii i Osteoporozy
Warsaw, 02-118
Slovakia5 sites
Reumatolog s.r.o.
Bratislava, 81108
AAGS, s.r.o. , nestatne zdravotnicke zariadenie
Dunajská Streda, 92901
Reumatologicka ambulancia, Ecclesia, s.r.o.
Nové Zámky, 94001
Narodny ustav reumatickych chorob
Piešťany, 921 12
Nestatna reumatologicka ambulancia
Žilina, 010 01
Spain5 sites
Hospital de Basurto
Bilbao, Vizcaya, 48013
Hospital General Universitario Gregorio Maranon
Madrid, 28007
Hospital Civil. Hospital Regional Universitario Carlos Haya
Málaga, 29009
Hospital Nuestra Señora de La Esperanza
Santiago de Compostela, A Coruña, 15705
Hospital Universitario Virgen Macarena
Seville, 41009
Mexico4 sites
Instituto Jaliscience de Investigación Clínica SA de CV
Guadalajara, Jalisco, 44158
Unidad de Investigacion en Enfermedades Cronico Degenerativas
Guadalajara, Jalisco, 44620
Hospital Universitario Jose Eleuterio Gonzalez
Monterrey, Nuevo León, 64020
Unidad de Enfermedades Reumaticas y Cronico Degenerativas SC
Torreón, Coahuila, 27000
New Zealand4 sites
The Canterbury Geriatric Medical Research Trust, c/- The Princess Margaret Hospital
Christchurch, 8022
Ryburns Building, Waikato Hospital
Hamilton, 3204
Centre for Clinical Research and Effective Practice (CCREP Middlemore Hospital
Otahuhu, Auckland, 1640
Timaru Hospital, Clinical Trials Unit
Timaru, 7910
Peru4 sites
Hospital Nacional IV Alberto Sabogal Sologuren
Callao, C-02
Clinica Anglo Americana
Lima, L 27
Centro Medico Corpac
Lima, L-27
Instituto Peruano del Hueso y la Articulacion SAC-Privado-Lima/Centro de Investigacion IPHAR
Lima, L-27
Argentina3 sites
OMI - Organización Médica de Investigación
Buenos Aires, C1015ABO
Saint Dennis Medical Group S.A.
Buenos Aires, C1034ACO
Consultorios Reumatológicos Pampa
Buenos Aires, C1428DZF
Australia3 sites
Emeritus Research
Malvern East, Victoria, 3145
Rheumatology Research Unit Sunshine Coast
Maroochydore, Queensland, 4558
The Queen Elizabeth Hospital, Department of Rheumatology
Woodville, South Australia, 5011
Colombia3 sites
Centro de Reumatologia y Ortopedia
Barranquilla, Atlántico
Centro Integral de Reumatologia e Inmunologia CIREI
Bogota, Cundinamarca, 0000
Servimed E.U
Bucaramanga, Santander Department
Malaysia3 sites
Sarawak General Hospital
Kuching, 93586
Sunway Medical Centre
Petaling Jaya, Selangor, 46150
Hospital Tuanku Ja'afar
Seremban, Negeri Sembilan, 70300
Philippines3 sites
Chong Hua Hospital
Cebu City, 6000
Brokenshire Integrated Health Ministries, Inc. Brokenshire Memorial Hospital
Davao City, 8000
Rayuma Klinik, OPD Department, Jose R. Reyes Memorial Medical Center
Manila, 1003
South Korea3 sites
Seoul National University Hospital, Rheumatology, Internal Medicine
Seoul, 110-744
Yonsei University College of Medicine, Severance Hospital, Rheumatology, Internal Medicine
Seoul, 120-752
Asan Medical Center, Rheumatology, Internal Medicine
Seoul, 138-736
Sweden3 sites
Skanes Universitetssjukhus i Malmo
Malmö, 205 02
Sundsvalls sjukhus- Medicinkliniken
Sundsvall, 851 86
Akademiska sjukhuset, Reumatologmottagningen
Uppsala, 751 85
Taiwan3 sites
Chung-Ho Memorial Hospital, Kaohsiung Medical University
Kaohsiung City, 807
Taichung Veterans General Hospital
Taichung, 407
National Cheng Kung University Hospital
Tainan, 704
Thailand3 sites
Rheumatology Unit, Department of Internal Medicine, Rajavithi Hospital
Bangkok, 10400
Siriraj Hospital, Mahidol University
Bangkok, 10700
Rheumatology Unit, Department of Internal Medicine, Phramongkutklao Hospital
Phayathai, Bangkok, 10400
Costa Rica2 sites
Centro de Reumatología y Osteoporosis, Cartago
Cartago, 00000
Hospital Cima San Jose
San José, 00000
Puerto Rico2 sites
Ponce School of Medicine
Ponce, 00716
Edificio Parra
Ponce, 00717-1321
Dominican Republic1 site
Patricia Alvarez Site
Santo Domingo, 00000
About this study
Official title: Phase 3 Randomized, Double-blind Study Of The Efficacy And Safety Of 2 Doses Of Cp-690,550 Compared To Methotrexate In Methotrexate Navie Patients With Rheumatoid Arthritis
This study is designed to compare the effectiveness of the experimental drug, CP-690,550, to methotrexate in preventing joint damage and improving symptoms of rheumatoid arthritis. This study will also compare the safety of CP-690,550 with methotrexate.
- Conditions
- Arthritis, Rheumatoid
- Being tested
- CP-690,550, Disease-modifying antirheumatic drug
- Keywords
- oral JAK inhibitor, MTX, DMARD, clinical trial, joint diseases, autoimmune diseases, anti-Inflammatory agents, rheumatic diseases
- Medical subject headings
- Arthritis, Rheumatoid, Joint Diseases, Autoimmune Diseases, Rheumatic Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CP-690,550Drug
Oral tablets administered at a dose of 5 mg BID for 24 months
CP-690,550Drug
Oral tablets administered at a dose of 10 mg BID for 24 months
Disease-modifying antirheumatic drugDrug
Also called DMARD, MTX
Oral capsules,administered as 10 mg per week for 4 weeks titrated to 15 mg per week for 4 weeks, then titrated to 20 mg week for 24 months
| Study group | Role | What they receive |
|---|---|---|
| 5 mg BID CP-690,550 | Experimental | Not described Receives: Drug: CP-690,550 |
| 10 mg BID CP-690,550 | Experimental | Not described Receives: Drug: CP-690,550 |
| methotrexate | Active comparator | Not described Receives: Drug: Disease-modifying antirheumatic drug |
What is being measured
The primary outcome is the main question the study is designed to answer.
Modified Total Sharp Score (mTSS) at Month 6
mTSS: sum of erosion and joint space narrowing (JSN) scores for 44 joints (16 per hand and 6 per foot). mTSS scores range from 0 (normal) to 448 (worst possible total score).
Measured: Month 6
Change From Baseline at Month 6 in mTSS
mTSS: sum of erosion and JSN scores for 44 joints (16 per hand and 6 per foot). mTSS scores range from 0 (normal) to 448 (worst possible total score). An increase in mTSS from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represents improvement.
Measured: Month 6
Percentage of Participants Achieving American College of Rheumatology 70 (ACR70) Response at Month 6
ACR70 response: greater than or equal to (≥) 70 percent (%) improvement in tender joints count (TJC) or swollen joints count (SJC) and ≥70% improvement in at least 3 of 5 remaining ACR core measures: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability (disability index of the Health Assessment Questionnaire [HAQ]), and 5) C-reactive protein (CRP).
Measured: Month 6
Absolute Blood Pressure (BP) Values (mmHg)
BP: pressure exerted by the blood upon the walls of the blood vessels and especially arteries, usually measured on the radial artery using a sphygmomanometer. Systolic BP: the highest arterial blood pressure of a cardiac cycle occurring immediately after systole of the left ventricle of the heart. Diastolic BP: the lowest arterial blood pressure of a cardiac cycle occurring during diastole of the heart.
Measured: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, and 24
Change From Baseline in BP Values (mmHg)
BP: pressure exerted by the blood upon the walls of the blood vessels and especially arteries, usually measured on the radial artery using a sphygmomanometer. Systolic BP: the highest arterial blood pressure of a cardiac cycle occurring immediately after systole of the left ventricle of the heart. Diastolic BP: the lowest arterial blood pressure of a cardiac cycle occurring during diastole of the heart.
Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, and 24
Secondary outcomes (83)
mTSS Score at Baseline, Months 12 and 24
mTSS: sum of erosion and JSN scores for 44 joints (16 per hand and 6 per foot). mTSS scores range from 0 (normal) to 448 (worst possible total score).
Measured: Baseline, Months 12 and 24
Change From Baseline in mTSS Score at Months 12 and 24
mTSS: sum of erosion and JSN scores for 44 joints (16 per hand and 6 per foot). mTSS scores range from 0 (normal) to 448 (worst possible total score). An increase in mTSS from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represents improvement.
Measured: Months 12 and 24
Percentage of Participants With no Progression in mTSS at Months 6, 12, and 24
mTSS: sum of erosion and JSN scores for 44 joints (16 per hand and 6 per foot). mTSS scores range from 0 (normal) to 448 (worst possible total score). A increase of less than or equal to (≤)0.5 in mTSS is considered to be no progression in the mTSS.
Measured: Months 6, 12, and 24
Percentage of Participants With no Worsening in Erosion Score (Increase ≤0.5) at Months 6, 12, and 24
Joint erosion score: erosion severity in 44 joints (16 per hand, 6 per foot). Each joint scored according to surface area involved, from 0 (no erosion) to 5 (extensive bone loss from more than one half of articulating bone). Because each side of foot joint was graded, maximum erosion score for foot joint was 10. Thus, maximum erosion score was 280. An increase of ≤0.5 in Erosion Score is considered to be 'no worsening' in the Erosion Score.
Measured: Months 6, 12, and 24
Erosion Scores
Joint erosion score: erosion severity in 44 joints (16 per hand, 6 per foot). Each joint scored according to surface area involved, from 0 (no erosion) to 5 (extensive bone loss from more than one half of articulating bone). Because each side of foot joint was graded, maximum erosion score for foot joint was 10. Thus, maximum erosion score was 280.
Measured: Baseline, Months 6, 12, and 24
JSN Scores
JSN score: severity of JSN in 42 joints (15 per hand and 6 per foot), including subluxation, scored from 0 (no/normal JSN) to 4 (complete loss of joint space, bony ankylosis, or luxation). Maximum JSN score was 168.
Measured: Baseline, Months 6, 12, and 24
Change From Baseline in Erosion Scores
Joint erosion score: erosion severity in 44 joints (16 per hand, 6 per foot). Each joint scored according to surface area involved, from 0 (no erosion) to 5 (extensive bone loss from more than one half of articulating bone). Because each side of foot joint was graded, maximum erosion score for foot joint was 10. Thus, maximum erosion score was 280. Change = score at observation minus score at Baseline. An increase in score from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.
Measured: Months 6, 12, and 24
Change From Baseline in JSN Scores
JSN score: severity of JSN in 42 joints (15 per hand and 6 per foot), including subluxation, scored from 0 (no/normal JSN) to 4 (complete loss of joint space, bony ankylosis, or luxation). Maximum JSN score was 168. Change = scores at observation minus score at Baseline. An increase in score from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.
Measured: Months 6, 12, and 24
Percentage of Participants Achieving an ACR70 Response
ACR70 response: ≥70% improvement in TJC or SJC and ≥70% improvement in at least 3 of 5 remaining ACR core measures: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability (disability index of HAQ), and 5) CRP.
Measured: Months 1, 2, 3, 9, 12, 15, 18, 21, and 24
Percentage of Participants Achieving an ACR20 Response
ACR20 response: ≥20% improvement in TJC or SJC and ≥20% improvement in at least 3 of 5 remaining ACR core measures: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability (disability index of HAQ), and 5) CRP.
Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Percentage of Participants Achieving an ACR50 Response
ACR50 response: ≥50% improvement in TJC or SJC and ≥50% improvement in at least 3 of 5 remaining ACR core measures: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability (disability index of HAQ), and 5) CRP.
Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Tender Joints Count (TJC)
Sixty-eight (68) joints were assessed by a blinded joint assessor to determine the number of joints considered tender or painful. The response to pressure/motion on each joint was assessed using the following scale: Present/Absent/Not Done/Not Applicable (to be used for artificial or missing joints). Artificial joints were not assessed. 68 joints to be assessed were: upper body (temporomandibular, sternoclavicular, acromioclavicular); upper extremity: shoulder, elbow, wrist (radiocarpal, carpal and carpometacarpal considered as one unit), metacarpophalangeals (MCP I, II, III, IV, V), thumb interphalangeal (IP), proximal interphalangeals (PIP II, III, IV, V), distal interphalangeals (DIP II, III, IV, V); lower extremity: hip, knee, ankle, tarsus (includes subtalar, transverse tarsal and tarsometatarsal considered as one unit), metatarsophalangeals (MTP I, II, III, IV, V), great toe IP, proximal and distal interphalangeals combined (PIP II, III, IV, V).
Measured: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Change From Baseline in TJC
Sixty-eight (68) joints were assessed by a blinded joint assessor to determine the number of joints considered tender or painful. The response to pressure/motion on each joint was assessed using the following scale: Present/Absent/Not Done/Not Applicable (to be used for artificial or missing joints). Artificial joints were not assessed. 68 joints to be assessed were: upper body (temporomandibular, sternoclavicular, acromioclavicular); upper extremity: shoulder, elbow, wrist (radiocarpal, carpal and carpometacarpal considered as one unit), MCP (I, II, III, IV, V), thumb IP, PIP (II, III, IV, V), DIP (II, III, IV, V); lower extremity: hip, knee, ankle, tarsus (includes subtalar, transverse tarsal and tarsometatarsal considered as one unit), MTP (I, II, III, IV, V), great toe IP, proximal and distal interphalangeals combined (PIP II, III, IV, V).
Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Swollen Joints Count (SJC)
Sixty-six (66) joints were assessed by a blinded joint assessor for swelling using the following scale: Present/Absent/Not Done/Not Applicable (to be used for artificial or missing joints). Artificial joints were not assessed. 66 joints assessed were: upper body (temporomandibular, sternoclavicular, acromioclavicular); upper extremity: shoulder, elbow, wrist (radiocarpal, carpal and carpometacarpal considered as one unit), MCP (I, II, III, IV, V), thumb IP, PIP (II, III, IV, V), DIP (II, III, IV, V); lower extremity: knee, ankle, tarsus (includes subtalar, transverse tarsal and tarsometatarsal considered as one unit), MTP (I, II, III, IV, V), great toe IP, proximal and distal interphalangeals combined (PIP II, III, IV, V).
Measured: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Change From Baseline in SJC
Sixty-six (66) joints were assessed by a blinded joint assessor for swelling using the following scale: Present/Absent/Not Done/Not Applicable (to be used for artificial or missing joints). Artificial joints were not assessed. 66 joints assessed were: upper body (temporomandibular, sternoclavicular, acromioclavicular); upper extremity: shoulder, elbow, wrist (radiocarpal, carpal and carpometacarpal considered as one unit), MCP (I, II, III, IV, V), thumb IP, PIP (II, III, IV, V), DIP (II, III, IV, V); lower extremity: knee, ankle, tarsus (includes subtalar, transverse tarsal and tarsometatarsal considered as one unit), MTP (I, II, III, IV, V), great toe IP, proximal and distal interphalangeals combined (PIP II, III, IV, V).
Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Patient Assessment of Arthritis Pain
Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) visual analogue scale (VAS), where 0 mm=no pain and 100 mm=most severe pain.
Measured: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Change From Baseline in Patient Assessment of Arthritis Pain
Participants rated the severity of arthritis pain on a 0 to 100 mm VAS, where 0 mm=no pain and 100 mm=most severe pain.
Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Physician Global Assessment of Arthritis
Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm=very good and 100 mm=very bad.
Measured: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Change From Baseline in Physician Global Assessment of Arthritis
Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm=very good and 100 mm=very bad.
Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Patient Global Assessment of Arthritis
Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS where 0=very well and 100=very poorly.
Measured: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Change From Baseline in Patient Global Assessment of Arthritis
Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS where 0=very well and 100=very poorly.
Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
C-Reactive Protein
CRP measured in milligrams per liter (mg/L)
Measured: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Change From Baseline in CRP
Change from Baseline in CRP measured in mg/L.
Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Disease Activity Score Based on 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3) CRP
DAS28-3(CRP) was calculated from the SJC and TJC using 28-joints count and CRP (mg/L). Total score range: 0 to approximately 10, higher score indicated more disease activity. DAS28-3(CRP) less than or equal to (≤)3.2 implied low disease activity, greater than (>)3.2 to 5.1 implied moderate disease activity, >5.1 implied high disease activity, and DAS28-3(CRP) less than (<)2.6 = remission.
Measured: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Disease Activity Score Based on 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR])
DAS28-4(ESR) was calculated from SJC and TJC using 28 joints count, ESR (millimeter/hour [mm/hour]) and patient's global assessment of disease activity (participant rated arthritis activity assessment). Total score range: 0 to approximately 10, higher score=more disease activity. DAS28-4(ESR) ≤3.2 implied low disease activity, >3.2 to 5.1 implied moderate disease activity, >5.1 implied high disease activity, and DAS28-4(ESR) <2.6 = remission.
Measured: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Change From Baseline in DAS28-3(CRP)
DAS28-3(CRP) was calculated from the SJC and TJC using 28-joints count and CRP (mg/L). Total score range: 0 to approximately 10, higher score indicated more disease activity. DAS28-3(CRP) ≤3.2 implied low disease activity, >3.2 to 5.1 implied moderate disease activity, >5.1 implied high disease activity, and DAS28-3(CRP) <2.6 = remission.
Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Change From Baseline in DAS28-4(ESR)
DAS28-4(ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hour) and patient's global assessment of disease activity (participant rated arthritis activity assessment). Total score range: 0 to approximately 10, higher score=more disease activity. DAS28-4(ESR) ≤3.2 implied low disease activity, >3.2 to 5.1 implied moderate disease activity, >5.1 implied high disease activity, and DAS28-4(ESR) <2.6 = remission.
Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Percentage of Participants With DAS28-3(CRP) ≤3.2
DAS28-3(CRP) was calculated from the SJC and TJC using 28-joints count and CRP (mg/L). Total score range: 0 to approximately 10, higher score indicated more disease activity. DAS28-3(CRP) ≤3.2 implied low disease activity, >3.2 to 5.1 implied moderate disease activity, >5.1 implied high disease activity, and DAS28-3(CRP) <2.6 = remission.
Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Percentage of Participants With DAS28-4(ESR) ≤3.2
DAS28-4(ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hour) and patient's global assessment of disease activity (participant rated arthritis activity assessment). Total score range: 0 to approximately 10, higher score=more disease activity. DAS28-4(ESR) ≤3.2 implied low disease activity, >3.2 to 5.1 implied moderate disease activity, >5.1 implied high disease activity, and DAS28-4(ESR) <2.6 = remission.
Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Percentage of Participants With DAS28-3(CRP) <2.6
DAS28-3(CRP) was calculated from the SJC and TJC using 28-joints count and CRP (mg/L). Total score range: 0 to approximately 10, higher score indicated more disease activity. DAS28-3(CRP) ≤3.2 implied low disease activity, >3.2 to 5.1 implied moderate disease activity, >5.1 implied high disease activity, and DAS28-3(CRP) <2.6 = remission.
Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Percentage of Participants With DAS28-4(ESR) <2.6
DAS28-4(ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hour) and patient's global assessment of disease activity (participant rated arthritis activity assessment). Total score range: 0 to approximately 10, higher score=more disease activity. DAS28-4(ESR) ≤3.2 implied low disease activity, >3.2 to 5.1 implied moderate disease activity, >5.1 implied high disease activity, and DAS28-4(ESR) <2.6 = remission.
Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Percentage of Participants With DAS28-3(CRP) Response (Good or Moderate Improvement)
DAS28-3(CRP) was calculated from the SJC and TJC using 28-joints count and CRP (mg/L). Total score range: 0 to approximately 10, higher score indicated more disease activity. DAS28 categorical responses define a good (absolute: <3.2 or >1.2 improvement from baseline [BL]), moderate (absolute: 3.2-5.1 or 0.6-1.2 change from BL), or no response (absolute: >5.1 or <0.6 change from BL).
Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Percentage of Participants With DAS28-4(ESR) Response (Good or Moderate Improvement)
DAS28-4(ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hour) and patient's global assessment of disease activity (participant rated arthritis activity assessment). Total score range: 0 to approximately 10, higher score=more disease activity. DAS28 categorical responses define a good (absolute: <3.2 or >1.2 improvement from BL), moderate (absolute: 3.2-5.1 or 0.6-1.2 change from BL), or no response (absolute: >5.1 or <0.6 change from BL).
Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Percentage of Participants With an ACR70 Response Sustained at Least 6 Months
ACR70 response: ≥70% improvement in TJC or SJC and ≥70% improvement in at least 3 of 5 remaining ACR core measures: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability (disability index of HAQ), and 5) CRP.
Measured: Months 6, 9, 12, 15, 18, 21, and 24
Percentage of Participants With Consecutive Visits of ACR20 Response by Number of Consecutive Visits
ACR20 response: ≥20% improvement in TJC or SJC and ≥20% improvement in at least 3 of 5 remaining ACR core measures: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability (disability index of HAQ), and 5) CRP.
Measured: Months 3, 6, 9, 12, 15, 18, 21, and 24
Percentage of Participants With Consecutive Visits of ACR50 Response by Number of Consecutive Visits
ACR50 response: ≥50% improvement in TJC or SJC and ≥50% improvement in at least 3 of 5 remaining ACR core measures: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability (disability index of HAQ), and 5) CRP.
Measured: Months 3, 6, 9, 12, 15, 18, 21, and 24
Percentage of Participants With Consecutive Visits of ACR70 Response by Number of Consecutive Visits
ACR70 response: ≥70% improvement in TJC or SJC and ≥70% improvement in at least 3 of 5 remaining ACR core measures: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability (disability index of HAQ), and 5) CRP.
Measured: Months 3, 6, 9, 12, 15, 18, 21, and 24
Percentage of Participants With Consecutive Visits of DAS28-3(CRP) <2.6 by Number of Consecutive Visits
DAS28-3(CRP) was calculated from the SJC and TJC using 28-joints count and CRP (mg/L). Total score range: 0 to approximately 10, higher score indicated more disease activity. DAS28-3(CRP) ≤3.2 implied low disease activity, >3.2 to 5.1 implied moderate disease activity, >5.1 implied high disease activity, and DAS28-3(CRP) <2.6 = remission.
Measured: Months 3, 6, 9, 12, 15, 18, 21, and 24
Percentage of Participants With Consecutive Visits of DAS28-4(ESR) <2.6 by Number of Consecutive Visits
DAS28-4(ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hour) and patient's global assessment of disease activity (participant rated arthritis activity assessment). Total score range: 0 to approximately 10, higher score=more disease activity. DAS28-4(ESR) ≤3.2 implied low disease activity, >3.2 to 5.1 implied moderate disease activity, >5.1 implied high disease activity, and DAS28-4(ESR) <2.6 = remission.
Measured: Months 3, 6, 9, 12, 15, 18, 21, and 24
Health Assessment Questionnaire Disability Index (HAQ-DI)
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom, arise, eat, walk, hygiene, common activities over past week. Each item scored on 4-point scale from 0-3: 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. Any activity that requires assistance from another individual or requires the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. Overall score was computed as sum of domain scores and divided by number of domains answered. Total possible score range 0-3: 0=least difficulty and 3=extreme difficulty.
Measured: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Change From Baseline in HAQ-DI Score
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom, arise, eat, walk, hygiene, common activities over past week. Each item scored on 4-point scale from 0-3: 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. Any activity that requires assistance from another individual or requires the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. Overall score was computed as sum of domain scores and divided by number of domains answered. Total possible score range 0-3: 0=least difficulty and 3=extreme difficulty.
Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Percentage of Participants With at Least 0.22 Improvement in HAQ-DI Score
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom, arise, eat, walk, hygiene, common activities over past week. Each item scored on 4-point scale from 0-3: 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. Any activity that requires assistance from another individual or requires the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. Overall score was computed as sum of domain scores and divided by number of domains answered. Total possible score range 0-3: 0=least difficulty and 3=extreme difficulty.
Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Percentage of Participants With at Least 0.3 Improvement in HAQ-DI Score
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom, arise, eat, walk, hygiene, common activities over past week. Each item scored on 4-point scale from 0-3: 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. Any activity that requires assistance from another individual or requires the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. Overall score was computed as sum of domain scores and divided by number of domains answered. Total possible score range 0-3: 0=least difficulty and 3=extreme difficulty.
Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Percentage of Participants With at Least 0.5 Improvement in HAQ-DI
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom, arise, eat, walk, hygiene, common activities over past week. Each item scored on 4-point scale from 0-3: 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. Any activity that requires assistance from another individual or requires the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. Overall score was computed as sum of domain scores and divided by number of domains answered. Total possible score range 0-3: 0=least difficulty and 3=extreme difficulty.
Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Short Form 36 (SF-36) Mental Component Score
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning.
Measured: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
SF-36 Physical Component Score
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning.
Measured: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Change From Baseline in SF-36 Mental Component Score
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning.
Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Change From Baseline in SF-36 Physical Component Score
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning.
Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
SF-36 Domain Scores
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Measured: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Change From Baseline in SF-36 Domain Scores
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Work Limitation Questionnaire (WLQ) Score
WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5-items); Physical Demands scale (6-item); Mental-Interpersonal Demands Scale (9-items); Output Demands scale (5-items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time).
Measured: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Change From Baseline in WLQ Scores
WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5 items); Physical Demands scale (6 items); Mental-Interpersonal Demands Scale (9 items); Output Demands scale (5 items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time).
Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
WLQ Work Loss Index Score
WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5-items); Physical Demands scale (6-item); Mental-Interpersonal Demands Scale (9-items); Output Demands scale (5-items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). Work Loss Index, which represented percentage of lost work over time period relative to a normative population, was derived (total score:0 [no loss] to 100 [complete loss of work]).
Measured: Baseline and Months 3, 6, and 12
Change From Baseline in WLQ Work Loss Index Score
WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5-items); Physical Demands scale (6-item); Mental-Interpersonal Demands Scale (9-items); Output Demands scale (5-items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). Work Loss Index, which represented percentage of lost work over time period relative to a normative population, was derived (total score:0 [no loss] to 100 [complete loss of work]).
Measured: Months 3, 6, 12, 15, 18, 21, and 24
European Quality of Life (EuroQol) Five Dimensions (EQ-5D) Health State Profile Utility Score
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
Measured: Baseline and Months 3, 6, 12, 18, and 24
Change From Baseline in EQ-5D Health State Profile Utility Score
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
Measured: Months 3, 6, 12, 18, and 24
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Months 3 and 6
Rheumatoid Arthritis (RA)-HCRU assessed healthcare usage during last 3 months for direct, indirect medical cost domains. Direct cost: visit to doctor, non-medical practitioner, nursing home, hospital, surgery, emergency room (ER) treatment, diagnostic tests, overnight stay, home healthcare services, aids/devices used. Indirect costs associated with functional disability: employment status, willingness to work, work disability due to RA, sick leave, part time work, ability to perform chores, chores done by family/friends/housekeeper. Assessment was based on 0 to 2-point scale; higher score=higher medical cost.
Measured: Baseline and Months 3 and 6
Work Productivity and Healthcare Resource Utilization (HCRU) at Months 12, 18, and 24
RA-HCRU assessed healthcare usage during last 3 months for direct, indirect medical cost domains. Direct cost: visit to doctor, non-medical practitioner, nursing home, hospital, surgery, ER treatment, diagnostic tests, overnight stay, home healthcare services, aids/devices used. Indirect costs associated with functional disability: employment status, willingness to work, work disability due to RA, sick leave, part time work, ability to perform chores, chores done by family/friends/housekeeper. Assessment was based on 0 to 2-point scale; higher score=higher medical cost.
Measured: Months 12, 18, and 24
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline and Months 3 and 6
RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA/non-RA related number of events including visits to doctor, non-medical practitioner, hospital ER treatment, hospitalizations, number of surgeries, diagnostic tests, and devices/aids used were reported.
Measured: Baseline and Months 3 and 6
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Months 12, 18, and 24
RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA/non-RA related number of events including visits to doctor, non-medical practitioner, hospital ER treatment, hospitalizations, number of surgeries, diagnostic tests, and devices/aids used were reported.
Measured: Months 12, 18, and 24
Number of Days as Assessed Using RA-HCRU at Baseline and Months 3 and 6
RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.
Measured: Baseline and Months 3 and 6
Number of Days as Assessed Using RA-HCRU at Months 12, 18, and 24
RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.
Measured: Months 12, 18, and 24
Number of Hours Per Day as Assessed Using RA-HCRU at Baseline and Months 3 and 6
RA-HCRU assessed healthcare (HC) usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home healthcare services, chores done by housekeeper, chores done by family or friends, work done, and work missed were reported.
Measured: Baseline and Months 3 and 6
Number of Hours Per Day as Assessed Using RA-HCRU at Months 12, 18, and 24
RA-HCRU assessed HC usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home healthcare services, chores done by housekeeper, chores done by family or friends, work done, and work missed were reported.
Measured: Months 12, 18, and 24
Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU
Work performance of participants on number of days bothered was based on a 0 to 10-point scale, where higher score indicated lower work performance.
Measured: Baseline, Months 3, 6, 12, 18, and 24
Change From Baseline in Work Productivity and HCRU at Months 3 and 6
RA-HCRU assessed HC usage during last 3 months for direct, indirect medical cost domains. Direct cost: visit to doctor, non-medical practitioner, nursing home, hospital, surgery, ER treatment, diagnostic tests, overnight stay, home healthcare services, aids/devices used. Indirect costs associated with functional disability: employment status, willingness to work, work disability due to RA, sick leave, part time work, ability to perform chores, chores done by family/friends/housekeeper. Assessment was based on 0 to 2-point scale; higher score=higher medical cost.
Measured: Months 3 and 6
Change From Baseline in Work Productivity and HCRU at Months 12, 18, and 24
RA-HCRU assessed HC usage during last 3 months for direct, indirect medical cost domains. Direct cost: visit to doctor, non-medical practitioner, nursing home, hospital, surgery, ER treatment, diagnostic tests, overnight stay, home healthcare services, aids/devices used. Indirect costs associated with functional disability: employment status, willingness to work, work disability due to RA, sick leave, part time work, ability to perform chores, chores done by family/friends/housekeeper. Assessment was based on 0 to 2-point scale; higher score=higher medical cost.
Measured: Months 12, 18, and 24
Change From Baseline in Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Months 3 and 6
RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA/non-RA related number of events including visits to doctor, non-medical practitioner, hospital ER treatment, hospitalizations, number of surgeries, diagnostic tests, and devices/aids used were reported.
Measured: Months 3 and 6
Change From Baseline in Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Months 12, 18, and 24
RA-HCRU assessed HC usage during previous 3 months for direct or indirect medical cost domains. Any RA/non-RA related number of events including visits to doctor, non-medical practitioner, hospital ER treatment, hospitalizations, number of surgeries, diagnostic tests, and devices/aids used were reported.
Measured: Months 12, 18, and 24
Change From Baseline in Number of Days as Assessed Using RA-HCRU at Months 3 and 6
RA-HCRU assessed HC usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.
Measured: Months 3 and 6
Change From Baseline in Number of Days as Assessed Using RA-HCRU at Months 12, 18, and 24
RA-HCRU assessed HC usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.
Measured: Months 12, 18, and 24
Change From Baseline in Number of Hours Per Day as Assessed Using RA-HCRU at Months 3 and 6
RA-HCRU assessed HC usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home HC services, chores done by housekeeper, chores done by family or friends, work done and work missed were reported.
Measured: Months 3 and 6
Change From Baseline in Number of Hours Per Day as Assessed Using RA-HCRU at Months 12, 18, and 24
RA-HCRU assessed HC usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home HC services, chores done by housekeeper, chores done by family or friends, work done and work missed were reported.
Measured: Months 12, 18, and 24
Change From Baseline in Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU
Work performance of participants on number of days bothered was based on a 0 to 10-point scale, where higher score indicated lower work performance.
Measured: Months 3, 6, 12, 18, and 24
Medical Outcomes Study Sleep Scale (MOS-SS) at Baseline and Months 1, 2, and 3
Participant-rated 12 item questionnaire to assess constructs of sleep over past week. 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range: 0-100); sleep quantity (range: 0-24), optimal sleep (yes or no). 9-item index measures of sleep disturbance provide composite scores: sleep problem summary, overall sleep problem. Except Adequacy, Optimal, Quantity of sleep, higher cores=more impairment. Scores transformed (actual raw score [RS] minus lowest possible score divided by possible RS range*100); total score range: 0-100, higher score=more intensity of attribute.
Measured: Baseline and Months 1, 2, and 3
Percentage of Participants With Optimal Sleep Assessed Using MOS-SS
MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Number of participants with optimal sleep are reported
Measured: Months 1, 2, 3, 6, 12, 18, and 24
Medical Outcomes Study Sleep Scale (MOS-SS) at Months 6, 12, 18, and 24
Participant-rated 12 item questionnaire to assess constructs of sleep over past week. 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range: 0-100); sleep quantity (range: 0-24), optimal sleep (yes or no). 9-item index measures of sleep disturbance provide composite scores: sleep problem summary, overall sleep problem. Except Adequacy, Optimal, Quantity of sleep, higher cores=more impairment. Scores transformed (actual raw score [RS] minus lowest possible score divided by possible RS range*100); total score range: 0-100, higher score=more intensity of attribute.
Measured: Months 6, 12, 18, and 24
Change From Baseline in MOS-SS at Months 1, 2, and 3
Participant-rated 12 item questionnaire to assess constructs of sleep over past week. 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range: 0-100); sleep quantity (range: 0-24), optimal sleep (yes or no). 9-item index measures of sleep disturbance provide composite scores: sleep problem summary, overall sleep problem. Except Adequacy, Optimal, Quantity of sleep, higher cores=more impairment. Scores transformed (actual raw score [RS] minus lowest possible score divided by possible RS range*100); total score range: 0-100, higher score=more intensity of attribute.
Measured: Months 1, 2, and 3
Change From Baseline in MOS-SS at Months 6, 12, 18, and 24
Participant-rated 12 item questionnaire to assess constructs of sleep over past week. 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range: 0-100); sleep quantity (range: 0-24), optimal sleep (yes or no). 9-item index measures of sleep disturbance provide composite scores: sleep problem summary, overall sleep problem. Except Adequacy, Optimal, Quantity of sleep, higher cores=more impairment. Scores transformed (actual raw score [RS] minus lowest possible score divided by possible RS range*100); total score range: 0-100, higher score=more intensity of attribute.
Measured: Months 6, 12, 18, and 24
Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale
FACIT-Fatigue is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status
Measured: Baseline and Months 1, 2, 3, 6, 12, 18, and 24
Change From Baseline in FACIT-Fatigue Scale
FACIT-Fatigue is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status
Measured: Months 1, 2, 3, 6, 12, 18, and 24
Change From Baseline in Heart Rate
Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Change From Baseline in Temperature
Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Dec 2009 (estimated)
- Study startJan 2010
- Primary completionMar 2013
- Study completionMar 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (26)Papers the sponsor has linked to this study.
- Other trials for Arthritis, RheumatoidStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 956 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01039688
- Sponsor's protocol ID
- A3921069
- Other IDs
- 2009-016987-34, 2009
- Acronym
- ORAL1069
- Status last verified
- Mar 2018
- First submitted
- 23 Dec 2009
- Last updated
- 6 Apr 2018
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Wright G, Mysler E, Roberts KD, Shelbaya A, Sweet L, Masri KR. Impact of the Sociodemographic Index on Efficacy/Safety of Tofacitinib in Patients with Rheumatoid Arthritis: Post Hoc Analysis of Phase 2/3/3b/4 Studies. Rheumatol Ther. 2026 Oct 16. doi: 10.1007/s40744-026-00881-y. Online ahead of print.
PubMed 42888330Hetland ML, Strangfeld A, Bonfanti G, Soudis D, Deuring JJ, Edwards RA. Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib. Arthritis Res Ther. 2024 Aug 27;26(1):153. doi: 10.1186/s13075-024-03376-9.
PubMed 39192350Wright GC, Mysler E, Kwok K, Cadatal MJ, Germino R, Yndestad A, Kinch CD, Ogdie A. Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials. Rheumatol Ther. 2024 Oct;11(5):1135-1164. doi: 10.1007/s40744-024-00677-y. Epub 2024 Jul 3.
PubMed 38958913Pope J, Finckh A, Silva-Fernandez L, Mandl P, Fan H, Rivas JL, Valderrama M, Montoro M. Tofacitinib Monotherapy in Rheumatoid Arthritis: Clinical Trials and Real-World Data Contextualization of Patients, Efficacy, and Treatment Retention. Open Access Rheumatol. 2024 Jun 11;16:115-126. doi: 10.2147/OARRR.S446431. eCollection 2024.
PubMed 38883150Ciurea A, Distler O, Kwok K, Jo H, Wang L, Killeen T, Ospelt C, Frank Bertoncelj M. Joint-level responses to tofacitinib and methotrexate: a post hoc analysis of data from ORAL Start. Arthritis Res Ther. 2023 Sep 29;25(1):185. doi: 10.1186/s13075-023-03144-1.
PubMed 37773189Charles-Schoeman C, Hyde C, Guan S, Parikh N, Wang J, Shahbazian A, Stockert L, Andrews J. Relationship Between Paraoxonase-1 Genotype and Activity, and Major Adverse Cardiovascular Events and Malignancies in Patients With Rheumatoid Arthritis Receiving Tofacitinib. J Rheumatol. 2023 Jul 15:jrheum.2023-0112. doi: 10.3899/jrheum.2023-0112. Online ahead of print.
PubMed 37453736Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, Rivas J, Benda B. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis. 2023 Jul;82(7):901-910. doi: 10.1136/ard-2022-223715. Epub 2023 Mar 17.
PubMed 36931693Dougados M, Taylor PC, Bingham CO 3rd, Fallon L, Brault Y, Roychoudhury S, Wang L, Kessouri M. The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis. RMD Open. 2022 Sep;8(2):e002478. doi: 10.1136/rmdopen-2022-002478.
PubMed 36814062Hansen KE, Mortezavi M, Nagy E, Wang C, Connell CA, Radi Z, Litman HJ, Adami G, Rossini M. Fracture in clinical studies of tofacitinib in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2022 Dec 27;14:1759720X221142346. doi: 10.1177/1759720X221142346. eCollection 2022.
PubMed 36601090Curtis JR, Yamaoka K, Chen YH, Bhatt DL, Gunay LM, Sugiyama N, Connell CA, Wang C, Wu J, Menon S, Vranic I, Gomez-Reino JJ. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023 Mar;82(3):331-343. doi: 10.1136/ard-2022-222543. Epub 2022 Dec 5.
PubMed 36600185Winthrop KL, Yndestad A, Henrohn D, Danese S, Marsal S, Galindo M, Woolcott JC, Jo H, Kwok K, Shapiro AB, Jones TV, Diehl A, Su C, Panes J, Cohen SB. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs. Rheumatol Ther. 2023 Apr;10(2):357-373. doi: 10.1007/s40744-022-00507-z. Epub 2022 Dec 17.
PubMed 36526796Dikranian AH, Gonzalez-Gay MA, Wellborne F, Alvaro-Gracia JM, Takiya L, Stockert L, Paulissen J, Shi H, Tatulych S, Curtis JR. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies. RMD Open. 2022 May;8(1):e002103. doi: 10.1136/rmdopen-2021-002103.
PubMed 35577477Winthrop KL, Curtis JR, Yamaoka K, Lee EB, Hirose T, Rivas JL, Kwok K, Burmester GR. Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. Rheumatol Ther. 2022 Feb;9(1):243-263. doi: 10.1007/s40744-021-00390-0. Epub 2021 Dec 6.
PubMed 34870800Bykerk VP, Lee EB, van Vollenhoven R, Gruben DC, Fallon L, Woolcott JC, Keystone E. Identification of Distinct Disease Activity Trajectories in Methotrexate-Naive Patients With Rheumatoid Arthritis Receiving Tofacitinib Over Twenty-Four Months. Arthritis Care Res (Hoboken). 2022 Jan;74(1):131-141. doi: 10.1002/acr.24709.
PubMed 34057820Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Wang L, Chen C, Kwok K, Biswas P, Shapiro A, Madsen A, Wollenhaupt J. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020 Oct;6(3):e001395. doi: 10.1136/rmdopen-2020-001395.
PubMed 33127856
Study at a glance
From the registry record, last updated by the sponsor on 6 Apr 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase 3 Randomized, Double-blind Study Of The Efficacy And Safety Of 2 Doses Of Cp-690,550 Compared To Methotrexate In Methotrexate Navie Patients With Rheumatoid Arthritis
- ClinicalTrials.gov ID
- NCT01039688
- Acronym / sponsor ID
- ORAL1069 / A3921069
- Conditions
- Arthritis, Rheumatoid
- Keywords
- oral JAK inhibitor, MTX, DMARD, clinical trial, joint diseases, autoimmune diseases, anti-Inflammatory agents, rheumatic diseases
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 956 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- Jan 2010 (actual)
- Primary completion
- Mar 2013 (actual)
- Study completion
- Mar 2013 (actual)
- First posted
- 25 Dec 2009 (estimated)
- Results
- Posted 6 Apr 2018
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is designed to compare the effectiveness of the experimental drug, CP-690,550, to methotrexate in preventing joint damage and improving symptoms of rheumatoid arthritis. This study will also compare the safety of CP-690,550 with methotrexate.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| 5 mg BID CP-690,550 | Experimental | Drug: CP-690,550 |
| 10 mg BID CP-690,550 | Experimental | Drug: CP-690,550 |
| methotrexate | Active comparator | Drug: Disease-modifying antirheumatic drug |
Who may qualify
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Adults with moderate to severe RA (Rheumatoid Arthritis) who have not been treated with methotrexate.
- Diagnosis of RA based on the American College of Rheumatology 1987 revised criteria.
- Active disease as defined by both >=6 tender or painful joints on motion and >= 6 joints swollen; and either an erythrocyte sedimentation rate (ESR) > 28 mm or a C-reactive protein (CRP) concentration > 7 mg/dL
Key exclusion criteria (5 listed)
- Blood dyscrasias including confirmed: Hemoglobin <9 g/dL or Hematocrit <30%; White blood cell count <3.0 x 109/L; Absolute neutrophil count <1.2 x 109/L; Platelet count <100 x 109/L
- History of any other rheumatic autoimmune disease other than Sjogren's syndrome
- No malignancy or history of malignancy
- History of infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator, within the 6 months prior to the first dose of study drug
- No chronic liver disease, recent or active hepatitis or other contraindication to methotrexate therapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CP-690,550Oral tablets administered at a dose of 5 mg BID for 24 months | Drug | 5 mg BID CP-690,550 |
| CP-690,550Oral tablets administered at a dose of 10 mg BID for 24 months | Drug | 10 mg BID CP-690,550 |
| Disease-modifying antirheumatic drugAlso: DMARD, MTXOral capsules,administered as 10 mg per week for 4 weeks titrated to 15 mg per week for 4 weeks, then titrated to 20 mg week for 24 months | Drug | methotrexate |
Primary outcome
Modified Total Sharp Score (mTSS) at Month 6
Time frame: Month 6
mTSS: sum of erosion and joint space narrowing (JSN) scores for 44 joints (16 per hand and 6 per foot). mTSS scores range from 0 (normal) to 448 (worst possible total score).
Change From Baseline at Month 6 in mTSS
Time frame: Month 6
mTSS: sum of erosion and JSN scores for 44 joints (16 per hand and 6 per foot). mTSS scores range from 0 (normal) to 448 (worst possible total score). An increase in mTSS from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represents improvement.
Percentage of Participants Achieving American College of Rheumatology 70 (ACR70) Response at Month 6
Time frame: Month 6
ACR70 response: greater than or equal to (≥) 70 percent (%) improvement in tender joints count (TJC) or swollen joints count (SJC) and ≥70% improvement in at least 3 of 5 remaining ACR core measures: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability (disability index of the Health Assessment Questionnaire [HAQ]), and 5) C-reactive protein (CRP).
Absolute Blood Pressure (BP) Values (mmHg)
Time frame: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, and 24
BP: pressure exerted by the blood upon the walls of the blood vessels and especially arteries, usually measured on the radial artery using a sphygmomanometer. Systolic BP: the highest arterial blood pressure of a cardiac cycle occurring immediately after systole of the left ventricle of the heart. Diastolic BP: the lowest arterial blood pressure of a cardiac cycle occurring during diastole of the heart.
Change From Baseline in BP Values (mmHg)
Time frame: Months 1, 2, 3, 6, 9, 12, 15, 18, and 24
BP: pressure exerted by the blood upon the walls of the blood vessels and especially arteries, usually measured on the radial artery using a sphygmomanometer. Systolic BP: the highest arterial blood pressure of a cardiac cycle occurring immediately after systole of the left ventricle of the heart. Diastolic BP: the lowest arterial blood pressure of a cardiac cycle occurring during diastole of the heart.
83 secondary outcomes
mTSS Score at Baseline, Months 12 and 24
Time frame: Baseline, Months 12 and 24
Change From Baseline in mTSS Score at Months 12 and 24
Time frame: Months 12 and 24
Percentage of Participants With no Progression in mTSS at Months 6, 12, and 24
Time frame: Months 6, 12, and 24
Percentage of Participants With no Worsening in Erosion Score (Increase ≤0.5) at Months 6, 12, and 24
Time frame: Months 6, 12, and 24
Erosion Scores
Time frame: Baseline, Months 6, 12, and 24
JSN Scores
Time frame: Baseline, Months 6, 12, and 24
Change From Baseline in Erosion Scores
Time frame: Months 6, 12, and 24
Change From Baseline in JSN Scores
Time frame: Months 6, 12, and 24
Percentage of Participants Achieving an ACR70 Response
Time frame: Months 1, 2, 3, 9, 12, 15, 18, 21, and 24
Percentage of Participants Achieving an ACR20 Response
Time frame: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Percentage of Participants Achieving an ACR50 Response
Time frame: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Tender Joints Count (TJC)
Time frame: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Change From Baseline in TJC
Time frame: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Swollen Joints Count (SJC)
Time frame: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Change From Baseline in SJC
Time frame: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Patient Assessment of Arthritis Pain
Time frame: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Change From Baseline in Patient Assessment of Arthritis Pain
Time frame: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Physician Global Assessment of Arthritis
Time frame: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Change From Baseline in Physician Global Assessment of Arthritis
Time frame: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Patient Global Assessment of Arthritis
Time frame: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Change From Baseline in Patient Global Assessment of Arthritis
Time frame: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
C-Reactive Protein
Time frame: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Change From Baseline in CRP
Time frame: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Disease Activity Score Based on 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3) CRP
Time frame: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Disease Activity Score Based on 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR])
Time frame: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Change From Baseline in DAS28-3(CRP)
Time frame: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Change From Baseline in DAS28-4(ESR)
Time frame: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Percentage of Participants With DAS28-3(CRP) ≤3.2
Time frame: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Percentage of Participants With DAS28-4(ESR) ≤3.2
Time frame: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Percentage of Participants With DAS28-3(CRP) <2.6
Time frame: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Percentage of Participants With DAS28-4(ESR) <2.6
Time frame: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Percentage of Participants With DAS28-3(CRP) Response (Good or Moderate Improvement)
Time frame: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Percentage of Participants With DAS28-4(ESR) Response (Good or Moderate Improvement)
Time frame: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Percentage of Participants With an ACR70 Response Sustained at Least 6 Months
Time frame: Months 6, 9, 12, 15, 18, 21, and 24
Percentage of Participants With Consecutive Visits of ACR20 Response by Number of Consecutive Visits
Time frame: Months 3, 6, 9, 12, 15, 18, 21, and 24
Percentage of Participants With Consecutive Visits of ACR50 Response by Number of Consecutive Visits
Time frame: Months 3, 6, 9, 12, 15, 18, 21, and 24
Percentage of Participants With Consecutive Visits of ACR70 Response by Number of Consecutive Visits
Time frame: Months 3, 6, 9, 12, 15, 18, 21, and 24
Percentage of Participants With Consecutive Visits of DAS28-3(CRP) <2.6 by Number of Consecutive Visits
Time frame: Months 3, 6, 9, 12, 15, 18, 21, and 24
Percentage of Participants With Consecutive Visits of DAS28-4(ESR) <2.6 by Number of Consecutive Visits
Time frame: Months 3, 6, 9, 12, 15, 18, 21, and 24
Health Assessment Questionnaire Disability Index (HAQ-DI)
Time frame: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Apr 2018.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 42888330Wright G, Mysler E, Roberts KD, Shelbaya A, Sweet L, Masri KR. Impact of the Sociodemographic Index on Efficacy/Safety of Tofacitinib in Patients with Rheumatoid Arthritis: Post Hoc Analysis of Phase 2/3/3b/4 Studies. Rheumatol Ther. 2026 Oct 16. doi: 10.1007/s40744-026-00881-y. Online ahead of print.
- Derived from this study: PubMed 39192350Hetland ML, Strangfeld A, Bonfanti G, Soudis D, Deuring JJ, Edwards RA. Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib. Arthritis Res Ther. 2024 Aug 27;26(1):153. doi: 10.1186/s13075-024-03376-9.
- Derived from this study: PubMed 38958913Wright GC, Mysler E, Kwok K, Cadatal MJ, Germino R, Yndestad A, Kinch CD, Ogdie A. Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials. Rheumatol Ther. 2024 Oct;11(5):1135-1164. doi: 10.1007/s40744-024-00677-y. Epub 2024 Jul 3.
- Derived from this study: PubMed 38883150Pope J, Finckh A, Silva-Fernandez L, Mandl P, Fan H, Rivas JL, Valderrama M, Montoro M. Tofacitinib Monotherapy in Rheumatoid Arthritis: Clinical Trials and Real-World Data Contextualization of Patients, Efficacy, and Treatment Retention. Open Access Rheumatol. 2024 Jun 11;16:115-126. doi: 10.2147/OARRR.S446431. eCollection 2024.
- Derived from this study: PubMed 37773189Ciurea A, Distler O, Kwok K, Jo H, Wang L, Killeen T, Ospelt C, Frank Bertoncelj M. Joint-level responses to tofacitinib and methotrexate: a post hoc analysis of data from ORAL Start. Arthritis Res Ther. 2023 Sep 29;25(1):185. doi: 10.1186/s13075-023-03144-1.
- Derived from this study: PubMed 37453736Charles-Schoeman C, Hyde C, Guan S, Parikh N, Wang J, Shahbazian A, Stockert L, Andrews J. Relationship Between Paraoxonase-1 Genotype and Activity, and Major Adverse Cardiovascular Events and Malignancies in Patients With Rheumatoid Arthritis Receiving Tofacitinib. J Rheumatol. 2023 Jul 15:jrheum.2023-0112. doi: 10.3899/jrheum.2023-0112. Online ahead of print.
- Derived from this study: PubMed 36931693Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, Rivas J, Benda B. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis. 2023 Jul;82(7):901-910. doi: 10.1136/ard-2022-223715. Epub 2023 Mar 17.
- Derived from this study: PubMed 36814062Dougados M, Taylor PC, Bingham CO 3rd, Fallon L, Brault Y, Roychoudhury S, Wang L, Kessouri M. The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis. RMD Open. 2022 Sep;8(2):e002478. doi: 10.1136/rmdopen-2022-002478.
- Derived from this study: PubMed 36601090Hansen KE, Mortezavi M, Nagy E, Wang C, Connell CA, Radi Z, Litman HJ, Adami G, Rossini M. Fracture in clinical studies of tofacitinib in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2022 Dec 27;14:1759720X221142346. doi: 10.1177/1759720X221142346. eCollection 2022.
- Derived from this study: PubMed 36600185Curtis JR, Yamaoka K, Chen YH, Bhatt DL, Gunay LM, Sugiyama N, Connell CA, Wang C, Wu J, Menon S, Vranic I, Gomez-Reino JJ. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023 Mar;82(3):331-343. doi: 10.1136/ard-2022-222543. Epub 2022 Dec 5.
- Derived from this study: PubMed 36526796Winthrop KL, Yndestad A, Henrohn D, Danese S, Marsal S, Galindo M, Woolcott JC, Jo H, Kwok K, Shapiro AB, Jones TV, Diehl A, Su C, Panes J, Cohen SB. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs. Rheumatol Ther. 2023 Apr;10(2):357-373. doi: 10.1007/s40744-022-00507-z. Epub 2022 Dec 17.
- Derived from this study: PubMed 35577477Dikranian AH, Gonzalez-Gay MA, Wellborne F, Alvaro-Gracia JM, Takiya L, Stockert L, Paulissen J, Shi H, Tatulych S, Curtis JR. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies. RMD Open. 2022 May;8(1):e002103. doi: 10.1136/rmdopen-2021-002103.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
Related trials for Arthritis, Rheumatoid
RecruitingPhase 2
Study of PTC844 in Participants With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Not yet recruitingPhase 1
An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)
Rheumatoid Arthritis and Systemic Lupus Erythematosus
Not yet recruitingPhase 1
R-2487 in Patients With Sjogren's Syndrome (SjD)
Sjogren's Syndrome, Sjögren
RecruitingPhase 1
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Active, not recruitingPhase 2
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
176 sites in 30 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing CP-690,550 and Disease-modifying antirheumatic drug in people with Arthritis, Rheumatoid, run by Pfizer at 176 sites in 30 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Apr 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 176 sites in United States, Russia, Canada, Germany, India and 25 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 6 Apr 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Modified Total Sharp Score (mTSS) at Month 6 (time frame: Month 6). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01039688, which also lists 26 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Apr 2018.